Rationale for Trials Studying Pegylated Liposomal Doxorubicin in Metastatic Breast Cancer

ONCOLOGY

Volumn 11, Issue 10 SUPPL. 12, 1997, Pages 45-53

  Jahanzeb, Mohammad ^a   Frankel, Cynthia ^b   Elkersh, Mohammed ^b   Koletsky, Alan ^b   Radice, Peter ^b   Vogel, Charles ^c  

^a JFK Comprehensive Cancer Center   (United States)

^b CCRG   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; CA 15-3 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EDATREXATE; ETOPOSIDE; FLUOROURACIL; FLUOXYMESTERONE; FOLINIC ACID; GEMCITABINE; LIPOSOME; MEGESTROL ACETATE; MELPHALAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; TAMOXIFEN CITRATE; THIOTEPA; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MICROENCAPSULATION; MUCOSA INFLAMMATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RASH;

EID: 2542615345     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. CDC: Breast and cervical cancer surveillance, United States, 1973-1987. In: CDC surveillance summaries (April). MMWR 41 (no. SS-2): 1-15, 1992.
2. Kosary CL, Ries LAG, Miller BA, et al, (eds): SEER cancer statistics review, 1973-1992: tables and graphs. Bethesda, Maryland: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute; publication no (NIH) 96-2789, 1995.
3. American Cancer Society. Cancer Facts and Figures, 1997. Atlanta, Georgia: American Cancer Society, publication no. 5008:96, 1997.
4. Harris JR, Lippman ME, Veronesi U, et al: Breast cancer. N Engl J Med 327:319-328, 1992.
5. Antman KH, Rowlings PA, Vaughan WP, et al. High dose chemotherapy with autologous hematopoetic stem cell support for breast cancer in North America. J Clin Oncol 15:1870-1879, 1997.
6. Hayes DF, Henderson IC: CAF in metastatic breast cancer: Standard therapy or another effective regimen. J Clin Oncol 5:1497-1499, 1987.
7. Muss HB, White DR, Richards F III, et al: Adriamycin versus, methotrexate in five-drug combination chemotherapy for advanced breast cancer. Cancer 42:2141-2148, 1978.
8. Tormey DC, Weinberg VE, Leone LA, et al: A comparison of intermittent vs continuous and of Adriamycin vs methotrexate 5-drug chemotherapy for advanced breast cancer. Am J Clin Oncol 7:231-239, 1984.
9. Smalley RV, Lefante J, Bartolucci A, et al: A comparison of cyclophosphamide, Adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat 3:209-220, 1983.
10. Bull J, Tormey D, Li SH, et al: A randomized comparative trial of Adriamycin versus methotrexate in combination drug therapy Cancer 41:1649-1657, 1978.
11. A'Hern RP, Smith IE, Ebbs SR: Chemothrepay and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67:801-805, 1993.
12. Von Hoff DD, Maxwell WL, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979.
13. Henderson IC, Allegra JC, Woodcock T, et al: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7:560-571, 1989.
14. Neidhart JA, Gochnour D, Roach R, et al: A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4:627-677, 1986.
15. Hainsworth JD, Andrews MB, Johnson DH, et al: Mitoxantrone, fluorouracil, and high-dose leucovorin: An effective, well-tolerated regimen for metastatic breast cancer. J Clin Oncol 9:1731-1735, 1991.
16. Jones SE, Mennel RG, Brooks B, et al: Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer J Clin Oncol 9:1736-1739, 1991.
17. Holmes FA, Walters RS, Thenault RL: Phase II trial of Taxol: An active drug in metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991.
18. Seidman A, Crown J, Reichman B, et al: Lack of clinical cross-resistance of Taxol (T) with anthracycline (A) in the treatment of metastatic breast cancer (MBC) (abstract 53). Proc Am Soc Clin Oncol 12:63, 1993.
19. Holmes FA, Valero V, Theriault RL, et al: Phase II trial of Taxol (T) in metastatic breast cancer (MBC) refractory to multiple prior treatments (abstract 178). Proc Am Soc Clin Oncol 12:94, 1993.
20. Fumoleau P, Chevallier B, Kerbrat P, et al: First line chemotherapy with Taxotere (T) in advanced breast cancer (ABC): A phase II study of the EORTC Clinical Screening Group (CSG) (abstract 27). Proc Am Soc Clin Oncol 12:56, 1993.
21. Ten Bokkel Huinink WW, Prove AM, Piccart M, et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer: A study of the EORTC Early Clinical Trials Group. Ann Oncol 5:527-532, 1994
22. Trudeau ME, Eisenhauer E, Lofters W, et al: Phase II study of Taxotere as first line chemotherapy for metastatic breast cancer (MBC). A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study (abstract 59). Proc Am Soc Clin Oncol 12:64, 1993.
23. Valero V, Walters R, Theriault R, et al: Phase II study of docetaxel (Taxotere) in anthracycline-refractory metastatic breast cancer (abstract 1636). Proc Am Soc Clin Oncol 13:470, 1994.
24. Taguchi T, Adachi I, Enomoto K, et al: Docetaxel (RP56976) in advanced or recurrent breast cancer: Early and late phase IT clinical studies in Japan (abstract 152). Proc Am Soc Clin Oncol 13:87, 1994.
25. Hortobagyi G: Docetaxel in breast cancer and a rationale for combination therapy. Oncology 11(6):11-15, 1997.
26. Rittenberg CN, Gralla RJ, Cole JT, et al. Preventing docetaxel-induced fluid retention: The efficacy of corticosteroids. Proc Am Soc Clin Oncol 15:531, 1996.
27. Schrijvers B, Wanders J, Dirix L, et al: Coping with toxicities of docetaxel. Ann Oncol 4:610-611, 1993.
28. Canobbio L, Boccardo F, Pastorino G, et al: Phase II study of Navelbine in advanced breast cancer. Semin Oncol 16:33-36, 1989.
29. Bruno S, Lira-Puerto V, Teixeira L, et al: Phase II trial with vinorelbine, (Navelbine, NVB) in the treatment of advanced breast cancer (ABC). Ann Oncol 3:268(a), 1992 (suppl 1).
30. Romero A, Rabinovich MG, Vallejo CT, et al: Vinorelbine as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 12:336-341, 1994.
31. Garcia-Conde J, Lluch A, Martin M, et al. Phase II trial of weekly IV Navelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 5:854-857, 1994.
32. Data on file, SEQUUS Pharmaceuticals.
33. Muggia FM, Hainsworth JD, Jeffers S, et al. Liposomal doxorubicin (Doxil) is active against refractory ovarian cancer. Proc Am Soc Clin Oncol 15:781, 1996.
34. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin (DOX-IL) in epithelial ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997.
35. Gabizon A, Uziely B, Lotem M, et al: Doxil in patients with pretreated metastatic breast cancer: A dose-schedule finding study with pharmacokinetics (abstract). Proc ASCO 16:516, 1997.
36. Harrington KJ, Mohammadtaghi S, Uster PS, et al. Stealth liposomes: A new targeting modality for solid tumors. In preparation
37. Uziely B, Jeffers S, Isacson R, et al: Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785, 1995.
38. Lokich JJ, Moore C: Chemotherapy-associated palmar-plantar erythrodysesthesis syndrome. Ann Intern Med 101:798-800, 1984.
39. Ranson MR, Carmichael J, O'Byrne K, et al: Treatment of advanced breast cancer with Stealth liposomal doxorubicin (CAELYX): Results of a multicenter phase II trial. J Clin Oncol 15:3185-3191, 1997.
40. Blajman C, Balbiam L, Coppola F, et al: Phase III study: Navelbine plus Adriamycin versus fluorouracil plus Adriamycin plus cyclophosphamide in advanced breast cancer. Proc 21st ESMO (abstract 112P), 1996.
41. Spielmann M, Dorval T, Turpin F, et al: Phase III trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12:1764-1770, 1994
42. Smalley R, Craig I, Jones S, et al: Navelbine and Adriamycin in combination for advanced breast cancer: Phase I-II evaluation of a new schedule. Proc ASCO 13 (abstract 157), 1994.
43. Hochster H, Vogel C, Blumenreich M, et al. A U.S. multicenter phase II study of Navelbine and doxorubicin as first line chemotherapy of metastatic breast cancer (abstract 258). Breast Cancer Res Treat 32(suppl):93, 1994.
44. Coppola F, Balbiani L, Blajman C, et al: Vinorelbine containing regimens in three different schedules for the treatment of advanced breast cancer (abstract 144). Proc ASCO 13, 1994.
45. Costa MA, Cabral-Filho S, Correa M, et al: Phase II sequential navelbine and doxorubicin for the treatment of metastatic breast cancer. Preliminary results (abstract 65). Proc ASCO 15, 1996
46. Firat D, Baltall E, Icli F, et al: Navelbine doxorubicin combination in advanced breast carcinoma previously untreated, (abstract 108P) Proc 21st ESMO, 1996.
47. Morris B, Pritchard K, James K, et al: A phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer (abstract 59). Proc ASCO 15, 1996.
48. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995.
49. Nabholtz JM, Mackey JR, Smylie M, et al: Phase II study of Taxotere (docetaxel), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC) Proc Am Soc Clin Oncol 16:148a, 1997.
50. Marty M, Extra JM, Dieras V, et al: A review of the antitumor activity of vinorelbine in breast cancer. Drugs 44(suppl 4):29-35, 1992.
51. Hayes DF, Henderson IC, Shapiro CL: Treatment of metastatic breast cancer: Present and future prospects. Semin Oncol 22:5-21, 1995.